TCRX - צמיחת הכנסות משנה לשנה ב-12 החודשים האחרונים TScan Therapeutics

The development of cellular cancer therapies creates a certain inertia, as the business relies on external capital without its own profitable products. The current year-over-year sales trend over 12 months confirms this dependency, where the parameter value equals -38.80. TScan Therapeutics (TCRX) leads in tumor receptor mapping while delegating production and clinical trials to external contractors.
TScan Therapeutics, Inc. - פילוחים אנליטיים ומדדי מפתח (TCRX)

The stability of TScan Therapeutics (TCRX) depends exclusively on the success of T-cell therapy clinical trials. Mathematically, this is reflected in the revenue dynamics over the last twelve months. This metric captures the percentage change in revenue, measuring the pace of business expansion. For a biotech startup without commercial products, the annual revenue growth rate over a rolling four quarters often remains zero due to R&D expenses.